MY204310A - Mast cell stabilizers for treatment of hypercytokinemia and viral infection - Google Patents
Mast cell stabilizers for treatment of hypercytokinemia and viral infectionInfo
- Publication number
- MY204310A MY204310A MYPI2019000588A MYPI2019000588A MY204310A MY 204310 A MY204310 A MY 204310A MY PI2019000588 A MYPI2019000588 A MY PI2019000588A MY PI2019000588 A MYPI2019000588 A MY PI2019000588A MY 204310 A MY204310 A MY 204310A
- Authority
- MY
- Malaysia
- Prior art keywords
- hypercytokinemia
- mast cell
- treatment
- viral infection
- cell stabilizers
- Prior art date
Links
- 206010050685 Cytokine storm Diseases 0.000 title abstract 3
- 206010052015 cytokine release syndrome Diseases 0.000 title abstract 3
- 210000003630 histaminocyte Anatomy 0.000 title abstract 3
- 208000036142 Viral infection Diseases 0.000 title abstract 2
- 239000003381 stabilizer Substances 0.000 title abstract 2
- 230000009385 viral infection Effects 0.000 title abstract 2
- 239000003443 antiviral agent Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000000087 stabilizing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662385021P | 2016-09-08 | 2016-09-08 | |
| PCT/US2017/050409 WO2018048989A1 (en) | 2016-09-08 | 2017-09-07 | Mast cell stabilizers for treatment of hypercytokinemia and viral infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY204310A true MY204310A (en) | 2024-08-22 |
Family
ID=61281984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2019000588A MY204310A (en) | 2016-09-08 | 2017-09-07 | Mast cell stabilizers for treatment of hypercytokinemia and viral infection |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US10501527B2 (enExample) |
| EP (1) | EP3509596B1 (enExample) |
| JP (1) | JP2019529541A (enExample) |
| KR (1) | KR20190073365A (enExample) |
| CN (1) | CN109952101A (enExample) |
| AU (2) | AU2017325010A1 (enExample) |
| BR (1) | BR112019004496A2 (enExample) |
| CA (1) | CA3036230A1 (enExample) |
| ES (1) | ES2988617T3 (enExample) |
| IL (1) | IL265208A (enExample) |
| MX (1) | MX389999B (enExample) |
| MY (1) | MY204310A (enExample) |
| PH (1) | PH12019500513A1 (enExample) |
| RU (1) | RU2760682C2 (enExample) |
| WO (1) | WO2018048989A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9925282B2 (en) | 2009-01-29 | 2018-03-27 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
| KR20190044647A (ko) | 2016-08-31 | 2019-04-30 | 더 제너럴 하스피탈 코포레이션 | 신경변성 질환과 관련된 신경-염증에서 대식세포/미세아교세포 |
| KR20190073365A (ko) | 2016-09-08 | 2019-06-26 | 이메르고 테라퓨틱스, 인코포레이티드 | 사이토카인 과분비 및 바이러스성 감염의 치료를 위한 비만 세포 안정화제 |
| JP2019533018A (ja) | 2016-10-18 | 2019-11-14 | エマーゴ セラピューティクス，インク． | 慢性炎症状態の処置の為の肥満細胞安定剤 |
| WO2020051322A1 (en) * | 2018-09-05 | 2020-03-12 | The General Hospital Corporation | Methods of treating cytokine release syndrome |
| CA3122989A1 (en) | 2018-12-10 | 2020-06-18 | The General Hospital Corporation | Cromolyn esters and uses thereof |
| US20200268734A1 (en) * | 2019-02-22 | 2020-08-27 | Bridge Pharma, Inc. | Methods of treatment of respiratory disorders |
| US10959992B2 (en) | 2019-02-22 | 2021-03-30 | Bridge Pharma Inc. | Methods of treatment of asthma and COPD |
| US20230346848A1 (en) * | 2020-03-06 | 2023-11-02 | Figene, Llc | Fibroblast and tlr activated fibroblast treatment of viral induced acute respiratory distress syndrome |
| JP2023520580A (ja) * | 2020-04-06 | 2023-05-17 | ザ ジェネラル ホスピタル コーポレイション | コロナウイルス誘発炎症状態の処置方法 |
| WO2023278381A1 (en) * | 2021-06-29 | 2023-01-05 | Bridge Pharma, Inc. | Treatment of dermal cytokine storm syndromes |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6878715B1 (en) | 1994-02-18 | 2005-04-12 | Cell Therapeutics, Inc. | Therapeutic compounds for inhibiting interleukin-12 signals and method for using same |
| AU6165798A (en) | 1997-02-18 | 1998-09-08 | Bridge Pharma, Inc. | Non-sedating histamine antagonist compounds, compositions and methods of use thereof |
| BR9807911A (pt) | 1997-04-03 | 2000-02-22 | Bridge Pharma Inc | Compostos benzocicloheptatiofeno |
| US6207684B1 (en) * | 1997-06-09 | 2001-03-27 | Bridge Pharma, Inc. | Compounds with combined antihistaminic and mast cell stabilizing activities, intended for ophthalmic use |
| CA2283603A1 (en) | 1998-10-01 | 2000-04-01 | Paul W. Behnke | Forced closed-loop cooling for a submersible pump motor |
| AU782816B2 (en) | 1999-09-13 | 2005-09-01 | Bridge Pharma, Inc. | Optically active isomers of ketotifen and therapeutically active metabolites thereof |
| US6680322B2 (en) | 1999-12-02 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| US20050249735A1 (en) | 2000-08-07 | 2005-11-10 | Centocor, Inc. | Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor |
| US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| US20030118670A1 (en) * | 2001-07-11 | 2003-06-26 | Smith C. Steven | Novel composition and method for altering allergenic protein in the environment |
| US6680299B2 (en) | 2001-07-27 | 2004-01-20 | Enanta Pharmaceuticals, Inc. | 4'-substituted leucomycins |
| US20060084695A1 (en) | 2004-04-29 | 2006-04-20 | John Griffin | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase |
| JP2009517404A (ja) | 2005-11-28 | 2009-04-30 | メディミューン，エルエルシー | Ｈｍｇｂ１および／またはｒａｇｅのアンタゴニストならびにその使用方法 |
| CN104614873A (zh) | 2006-09-29 | 2015-05-13 | 庄臣及庄臣视力保护公司 | 用于治疗眼变态反应性的方法和眼科装置 |
| US20080139531A1 (en) | 2006-12-04 | 2008-06-12 | Alcon Manufacturing Ltd. | Use of connective tissue mast cell stabilizers to facilitate ocular surface re-epithelization and wound repair |
| WO2008153761A1 (en) * | 2007-05-23 | 2008-12-18 | Mastcell Pharmaceuticals, Inc. | Methods |
| EP2214503A1 (en) | 2007-10-15 | 2010-08-11 | Revolymer Limited | Solvent-free synthesis of amphiphilic polymeric material |
| CN101821989A (zh) | 2007-12-24 | 2010-09-01 | 中兴通讯股份有限公司 | 一种光传输系统的通道共享保护方法及装置 |
| CN101990437A (zh) * | 2008-01-04 | 2011-03-23 | 阿尔康药品有限公司 | 稳定的环孢菌素水性组合物 |
| WO2009142772A2 (en) | 2008-05-23 | 2009-11-26 | Mastcell Pharmaceuticals, Inc. | Methods and treatment for allergies and inflammation associated with gastrointestinal diseases |
| US8741930B2 (en) | 2008-10-24 | 2014-06-03 | Bridge Pharma, Inc. | Treating xerophthalmia with norketotifen |
| WO2010059894A1 (en) | 2008-11-21 | 2010-05-27 | Bridge Pharma, Inc. | Ocular formulations of norketotifen |
| CA2754996A1 (en) | 2009-03-17 | 2010-09-23 | Aciex Therapeutics, Inc. | Ophthalmic formulations of ketotifen and methods of use |
| WO2010106016A1 (en) | 2009-03-17 | 2010-09-23 | Glaxo Group Limited | Pyrimidine derivatives used as itk inhibitors |
| CA2780453A1 (en) | 2009-12-02 | 2011-06-09 | Bridge Pharma, Inc. | Treating xerophthalmia with compounds increasing meibomian gland secretion |
| HUE033063T2 (hu) | 2010-05-14 | 2017-11-28 | Abbvie Inc | IL-1 kötõ fehérjék |
| UY33492A (es) | 2010-07-09 | 2012-01-31 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| JP2014520847A (ja) | 2011-07-13 | 2014-08-25 | アッヴィ・インコーポレイテッド | 抗ｉｌ−１３抗体を使用して喘息を治療するための方法および組成物 |
| WO2014040112A1 (en) | 2012-09-17 | 2014-03-20 | Guina Research & Development Pty Ltd | Electromagnetic turbine |
| US8557846B1 (en) | 2012-10-23 | 2013-10-15 | Bridge Pharma, Inc. | Medicinal treatment of dermal diseases in dogs |
| US8778971B2 (en) | 2012-10-23 | 2014-07-15 | Bridge Pharma, Inc. | Medicinal treatment of dermal diseases in companion animals |
| US20140120121A1 (en) | 2012-10-30 | 2014-05-01 | Bridge Pharma, Inc. | Medicinal treatment of atopic inflammatory diseases |
| US20150272941A1 (en) | 2012-10-30 | 2015-10-01 | Bridge Pharma, Inc. | Medicinal treatment of chronic pulmonary inflammatory diseases with norketotifen |
| US9347325B2 (en) | 2012-10-31 | 2016-05-24 | Solar Turbines Incorporated | Damper for a turbine rotor assembly |
| JP6084473B2 (ja) | 2013-02-01 | 2017-02-22 | 日立オートモティブシステムズ株式会社 | 複合センサ |
| US9439895B2 (en) | 2013-08-06 | 2016-09-13 | Bridge Pharma, Inc. | Methods of treating pruritic conditions mediated through non-histaminergic mechanisms in diabetic patients |
| US9345697B2 (en) | 2013-08-06 | 2016-05-24 | Bridge Pharma, Inc. | Methods of treatment of non-histaminic pruritus |
| US9138431B2 (en) * | 2013-08-06 | 2015-09-22 | Bridge Pharma, Inc. | Methods of treatment of histamine H-4 receptor-related pruritus |
| WO2015120389A1 (en) | 2014-02-10 | 2015-08-13 | Patara Pharma, LLC | Mast cell stabilizers treatment for systemic disorders |
| US10293352B2 (en) | 2015-02-13 | 2019-05-21 | Kärcher North America, Inc. | Hand held fluid dispensing apparatus |
| CA2976369A1 (en) | 2015-02-13 | 2016-08-18 | Yale University | Biaryltriazole inhibitors of macrophage migration inhibitory factor |
| WO2017035418A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Disubstituted compounds for treatment of immune and inflammatory disorders |
| US9694003B2 (en) | 2015-10-15 | 2017-07-04 | Bridge Pharma, Inc. | Formulations and methods for treating high intraocular pressure |
| KR20190073365A (ko) | 2016-09-08 | 2019-06-26 | 이메르고 테라퓨틱스, 인코포레이티드 | 사이토카인 과분비 및 바이러스성 감염의 치료를 위한 비만 세포 안정화제 |
| JP2019533018A (ja) | 2016-10-18 | 2019-11-14 | エマーゴ セラピューティクス，インク． | 慢性炎症状態の処置の為の肥満細胞安定剤 |
-
2017
- 2017-09-07 KR KR1020197010083A patent/KR20190073365A/ko not_active Ceased
- 2017-09-07 WO PCT/US2017/050409 patent/WO2018048989A1/en not_active Ceased
- 2017-09-07 BR BR112019004496A patent/BR112019004496A2/pt not_active Application Discontinuation
- 2017-09-07 MY MYPI2019000588A patent/MY204310A/en unknown
- 2017-09-07 MX MX2019002781A patent/MX389999B/es unknown
- 2017-09-07 CA CA3036230A patent/CA3036230A1/en active Pending
- 2017-09-07 ES ES17849505T patent/ES2988617T3/es active Active
- 2017-09-07 CN CN201780068796.6A patent/CN109952101A/zh active Pending
- 2017-09-07 EP EP17849505.7A patent/EP3509596B1/en active Active
- 2017-09-07 AU AU2017325010A patent/AU2017325010A1/en not_active Abandoned
- 2017-09-07 US US15/697,835 patent/US10501527B2/en active Active
- 2017-09-07 JP JP2019535191A patent/JP2019529541A/ja active Pending
- 2017-09-07 RU RU2019110150A patent/RU2760682C2/ru active
- 2017-11-17 US US15/816,461 patent/US10160796B2/en active Active
-
2018
- 2018-11-15 US US16/192,385 patent/US10494420B2/en active Active
-
2019
- 2019-03-07 IL IL265208A patent/IL265208A/en unknown
- 2019-03-08 PH PH12019500513A patent/PH12019500513A1/en unknown
- 2019-10-25 US US16/664,037 patent/US10787502B2/en active Active
- 2019-10-25 US US16/664,039 patent/US11072648B2/en active Active
-
2023
- 2023-06-23 AU AU2023204000A patent/AU2023204000A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN109952101A (zh) | 2019-06-28 |
| AU2017325010A1 (en) | 2019-03-28 |
| US20180066039A1 (en) | 2018-03-08 |
| KR20190073365A (ko) | 2019-06-26 |
| ES2988617T3 (es) | 2024-11-21 |
| AU2023204000A1 (en) | 2023-07-13 |
| PH12019500513A1 (en) | 2019-05-27 |
| US20190085057A1 (en) | 2019-03-21 |
| EP3509596A1 (en) | 2019-07-17 |
| US10494420B2 (en) | 2019-12-03 |
| US10787502B2 (en) | 2020-09-29 |
| RU2019110150A (ru) | 2020-10-08 |
| EP3509596B1 (en) | 2024-07-03 |
| IL265208A (en) | 2019-05-30 |
| MX2019002781A (es) | 2019-09-04 |
| JP2019529541A (ja) | 2019-10-17 |
| EP3509596A4 (en) | 2020-05-06 |
| RU2760682C2 (ru) | 2021-11-29 |
| US20180072796A1 (en) | 2018-03-15 |
| CA3036230A1 (en) | 2018-03-15 |
| US20200055926A1 (en) | 2020-02-20 |
| RU2019110150A3 (enExample) | 2020-12-18 |
| EP3509596C0 (en) | 2024-07-03 |
| WO2018048989A1 (en) | 2018-03-15 |
| MX389999B (es) | 2025-03-11 |
| US20200055927A1 (en) | 2020-02-20 |
| US10501527B2 (en) | 2019-12-10 |
| BR112019004496A2 (pt) | 2019-05-28 |
| US10160796B2 (en) | 2018-12-25 |
| US11072648B2 (en) | 2021-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019500513A1 (en) | Mast cell stabilizers for treatment of hypercytokinemia and viral infection | |
| JOP20180123A1 (ar) | مركبات علاجية مفيدة للوقاية من أو علاج الإصابة بفيروس نقص المناعة البشرية | |
| PH12018500573A1 (en) | Hepatitis b core protein modulators | |
| PH12016501254A1 (en) | Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection | |
| JOP20180008A1 (ar) | مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b | |
| PH12016501379A1 (en) | Azepane derivatives and methods of treating hepatitis b infections | |
| MX2020012560A (es) | Metodos para tratar infecciones por el virus de filoviridae. | |
| EA201791515A1 (ru) | Соединения пиразина для лечения инфекционных заболеваний | |
| PH12017500393A1 (en) | Pyrrolopyrimidines for use in influenza virus infection | |
| MX2021004464A (es) | Compuestos de tiazolida para el tratamiento de infecciones virales. | |
| MX2017000312A (es) | Derivados de isoindolina para usarse en el tratamiento de una infeccion viral. | |
| MX2018002707A (es) | Derivados de tetrahidrofurano antivirales. | |
| BR112017026061A2 (pt) | composto, uso de um composto, e, método de tratamento de uma infecção viral | |
| PH12016500320A1 (en) | Cyclosporin analogues for preventing or treating hepatitis c | |
| GB2544439A (en) | Antiviral composition | |
| PH12018501624A1 (en) | A composition comprising pic for treatment of cancer | |
| EA201890653A1 (ru) | Композиция с противовирусным эффектом | |
| PH12017500816A1 (en) | Long acting pharmaceutical compositions for hepatitis c | |
| PH12017500820A1 (en) | Combination long acting compositions and methods for hepatitis c | |
| JOP20190214A1 (ar) | ثنائي هيدرو إيندين-?-كربوكساميدات ونظائر منها بها استبدال، وطرق تستخدمها | |
| PH12019502145A1 (en) | Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient | |
| MX2016012104A (es) | Compuestos de azabenzofurano que contienen ciano para el tratamiento de la hepatitis c. | |
| MX2017014463A (es) | Cabazitaxel y su uso para tratar cancer. | |
| SG10201903630UA (en) | Iminosugars useful for the treatment of viral diseases | |
| GEP20197007B (en) | Therapeutic agent for frontal lobe dysfunction |